Clinical Trials
12 trialsNCT03578081 2025-04-06
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT01836705 2025-03-05
Effect of SAR302503 on ECG Activity in Patients With Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT03040726 2023-10-17
Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer
M.D. Anderson Cancer Center
Phase 2/3 Completed
NCT03097588 2021-07-12
Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant
OHSU Knight Cancer Institute
Phase 2 Completed
NCT02532634 2018-05-11
RAPA
Kangdong Sacred Heart Hospital
Phase 4 Completed
NCT00684463 2017-05-16
Palonosetron in Moderately and Highly Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04935)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT00687011 2017-05-15
Palonosetron Plus Dexamethasone in Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04594)
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT00600353 2017-03-09
Multi-day Doses in Prevention of Nausea and Emesis
University of Kansas Medical Center
Phase 2 Completed
NCT02203253 2016-08-24
Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting
China Medical University, China
Phase 3 Completed
NCT01909856 2015-12-04
The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 2 Completed
NCT01640340 2013-11-07
Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)
Ohio State University Comprehensive Cancer Center
Phase NA Completed
NCT01481831 2012-12-31
ESPNV
Shanghai Changzheng Hospital
Phase 4 Completed